No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura [1]

European Journal of Surgical Oncology

Volumn 28, Issue 5, 2002, Pages 564-565

  Mudhar, H S ^a   Fisher, P M ^b   Wallace, W A H ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CD20 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; GENERAL HOSPITAL; HISTOPATHOLOGY; HOSPITAL DEPARTMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; SCORING SYSTEM; SOUTH AFRICA; T LYMPHOCYTE ACTIVATION; THORAX RADIOGRAPHY; TISSUE SECTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY;

EID: 0036704354     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1294     Document Type: Editorial

References (10)

1. Antman KH, Li FP, Pass HI. Benign and malignant mesothelioma. In DeVita VT Jr, Hellman S. Rosenberg SA eds Cancer: Principles and Practice of Oncology. 4th edn. Philadelphia: Lippencott, 1993; 1489-508.
2. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68: 356-62.
3. Clark WH Jr, Elder DE, Guerry D IV, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989; 81: 1893-904.
4. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, Jeffrey RR. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000; 27: 27-35.
5. Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thoracic & Cardiovasc Surg 2001; 121: 1058-63.
6. Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982; 61: 1007-9.
7. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopath 1997; 30: 404-18.
8. Jarnicki AG, Fitzpatrick DR, Robinson BW, Bielefeldt-Ohmann H. Altered CD3 chain cytokine gene expression in tumour infiltrating T lymphocytes during the development of mesothelioma. Cancer Lett 1996; 103: 1-9.
9. Phillips JH, Takeshita T, Sugamura K, Lanier LL. Activation of natural killer cells via the p75 interlekin 2 receptor. J Exp Med 1989; 170: 291-6.
10. Astoul P, Picat-Joosen D, Viallat JR et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma. A phase II study. Cancer 1998; 83: 2099-104.